NCT02085538View on ClinicalTrials.gov

Study Of Palbociclib (PD-0332991) In Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions

Renal Impairment

Interventions

DRUG

palbociclib

palbociclib 125 mg oral capsule with food once

DRUG

palbociclib

palbociclib 125 mg oral capsule with food once

DRUG

palbociclib

palbociclib 125 mg oral capsule with food once

DRUG

palbociclib

palbociclib 125 mg oral capsule with food once

Trial Locations (3)

32720

Avail Clinical Research, LLC, DeLand

32809

Orlando Clinical Research Center, Orlando

55114

Prism Research, Saint Paul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT02085538 - Study Of Palbociclib (PD-0332991) In Renal Impairment | Biotech Hunter | Biotech Hunter